Cancer biotech Calithera Biosciences files for a $80 million IPO

By
A A A

Calithera Biosciences, an early-stage biotech developing a drug platform for tumor metabolism and immunology, filed on Monday with the SEC to raise up to $80 million in an initial public offering.

The San Francisco, CA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol CALA. Calithera Biosciences initially filed confidentially on July 25, 2014. Citi, Leerink Partners, Wells Fargo Securities and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer biotech Calithera Biosciences files for a $80 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com